Molnupiravir: all 24 studies that test it
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)RecruitingNCT06667700Phase 3
- Adaptive Dengue Antiviral Platform TrialRecruitingNCT06551844Phase 2
- Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingNCT06488300Phase 2
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaRecruitingNCT05648448Phase 2
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingNCT05041907Phase 2
- AGILE (Early Phase Platform Trial for COVID-19)RecruitingNCT04746183Phase 1/2
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)CompletedNCT05818124Phase 1Results posted
- Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)CompletedNCT05559905Phase 2Results posted
- A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)CompletedNCT05386758Phase 1Results posted
- A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)CompletedNCT05386589Phase 1Results posted
- Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)CompletedNCT04939428Phase 3Results posted
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)CompletedNCT04575597Phase 2/3Results posted
- Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)TerminatedNCT04575584Phase 2/3Results posted
- The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)CompletedNCT04405739Phase 2Results posted
- Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19CompletedNCT04405570Phase 2Results posted
- COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy VolunteersCompletedNCT04392219Phase 1Results posted
- A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)CompletedNCT06816030Phase 1
- A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)CompletedNCT06615869Phase 1
- Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)CompletedNCT05648799Not applicable
- Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19CompletedNCT05595824Phase 3
- A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South AfricaCompletedNCT05459532Phase 2/3
- Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy VolunteersCompletedNCT05412173Not applicable
- The DAWN Antivirals Trial for Ambulatory COVID-19 PatientsTerminatedNCT04730206Phase 3